

RECEIVED
CENTRAL FAX CENTER

OCT 17 2005

FAX



GlaxoSmithKline

To Art Unit 1614
.....
Company USPTO
.....
Fax 571-273-8300
.....
From Valerie L. Phillips
.....
Tel 919-483-8223 Fax 919-483-5730
.....
E-mail valerie.l.phillips@gsk.com
.....
Date October 17, 2005 Pages including cover 22
Subject Supplemental IDS/w PTO1449
.....

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 10/530,101
Date: April 1, 2005
Applicant: Gudmundsson et al.
Title: Therapeutic Compounds Based on Pyrazolopyridine Derivatives

Attached:
Supplemental IDS
PTO 1449 w/3 references
Certificate of Transmission

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 571-273-8300) on October 17, 2005.

Valerie L. Phillips

Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PU4959USW

OCT 17 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gudmundsson et al.

Serial No.: 10/530,101

Group Art Unit:

File Date: April 1, 2005

Examiner: 1614

For: Therapeutic Compounds Based on Pyrazolopyridine Derivatives

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed:

☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan
Registration No. 38,181

Date: 17 Oct 2005
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

